REsolution oF thrombi in Left atrial appendage with EdoXaban

Keimyung University Dongsan Medical Center0 个研究点目标入组 60 人开始时间: 待定最近更新: 2019年3月25日

适应症

试验速览

暂无简介。

•Men or women aged = 19 years, <80 years
•Hemodynamically stable nonvalvular AF or atrial flutter
•VKA or NOAC-naïve or untreated within 1 month prior to sign the informed consent
•LAA thrombus documented by TEE up to 72 hours prior to start of study medication
•A person who understands the written description of the research method and has completed the written consent form

•Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months or any stroke within 14 days before the start of study drug
•Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to study inclusion
•Acute myocardial infarction within the last 14 days prior to study inclusion
•Cardiac-related criteria: Previous intracardiac thrombus, Free-floating ball thrombus, Intracardiac tumor, known left ventricular or aortic thrombus
•Active bleeding or high risk for bleeding contraindicating anticoagulant therapy
•i. Current history or history of hemorrhage or coagulation disorders
•ii. Thrombocytopenia
•iii. Pregnant patient
•Patients who can not follow up after medication

发起方